◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksRDY › EPS

Dr. Reddy’s Laboratories Ltd ADR (RDY) EPS 2007–TTM

DATA UPDATED 2026-07-29

Dr. Reddy’s Laboratories Ltd ADR annual earnings per share (EPS) for fiscal TTM was ₹39.81, a decrease of 26.4% from ₹54.11 in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

RDY Annual EPS

EPS (annual)TTM → 2026-06-302026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-312007-03-31
Earnings Per Share (EPS)₹39.81₹54.11₹67.77₹66.80₹54.17₹28.34₹0.28₹23.48₹22.62₹11.80₹14.42₹23.40₹25.95₹25.21₹19.69₹16.76₹12.99₹1.26₹-6.14₹5.55₹11.74

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RDY Quarterly EPS

EPS (quarterly)2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Earnings Per Share (EPS)₹5.36₹2.68₹14.52₹17.25₹17.02₹19.10₹16.94₹15.05

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EPS at Comparable Companies

More RDY metrics: Revenue · Gross Profit · Operating Income · Net Income · EBITDA · Free Cash Flow · Shares Outstanding

All RDY financial statements → Interactive RDY charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.